

23rd Annual South Florida Residency Seminar

Navigating Current Events - Challenges, Opportunities, and Hope January 26 and 27, 2019 (50-2488; Med Error 20-464633, GCE,RCE,TCE 20-679820)

Our presenters are the post-graduate Pharmacy Residents who are completing their training at South Florida facilities including Baptist Health of Miami (BHM), Homestead Hospital (HH), Larkin Hospital (LH), Memorial Regional Hospital South (MRHS), Memorial Hospital West (MHW), Mercy Hospital (MH), Miami VA Healthcare System (MVA), Nicklaus Children's Hospital (NCH), Nova Southeastern University (NSU), Palmetto General Hospital (PGH), South Miami Baptist (SMB), University of Miami Hospital (UMH), and West Kendall Baptist Hospital (WKBH). Thanks to them and their preceptors for sharing in their experiences. NOTE: This course is NOT an ACPE accredited program. Credits are posted to CE Broker only.

The Dade County Pharmacy Association is proudly celebrating the 23rd year presenting the Residency Program. This year, we still have two tracks each day, however, they have the same content. No need to pick a track based upon content. The program is intended to be the same across all tracks on each day. This double tracking allows all 34 South Florida Pharmacy Residents ample time to present as well

_	intimate class size. This year we are also offering the required Medication Errors Course. We will annually alternate ourse and Controlled Substance Prescription Validation to provide the required credits needed for licensure renewal.
	base our annual Free Raffle this year. Be sure you receive your Raffle ticket and bring it back on Sunday to participate.
8:00-9:55am	Medication Errors. Presenters Track 1 - Marry Vuong, PharmD, PGY1 (NCH); Track 2 - Sabrina Oweisi, PharmD,
8.00-3.33am	PGY1 (NCH). At the end of this session participants will be able to:
2hr GCE, TCE	
or	Define and describe common causes and three strategies to decrease of medications errors. Describe magning and purpose of root spuce applying in the investigation of medication errors.
Medication	Describe meaning and purpose of root cause analysis in the investigation of medication errors. Given a scenario, be able to categorize and/or report medication errors utilizing the NCCR MERR scale.
Errors	• Given a scenario, be able to categorize and/or report medication errors utilizing the NCCP MERP scale.
LITOIS	 Identify strategies, the role of technology and the importance of non-punitive approach for handling medication errors after errors have occurred.
9:55am-10:05a	
10:05-	Opioid crisis! It is now or never! Presenters Track 1 – Huy Pham, PharmD, PGY1 Community (NSU); Track 2 –
10:55am	Justin Ritter, PharmD, PGY1 (MVA). At the end of this session participants will be able to:
	• Understand Florida's new law on controlled substance prescribing and reveal loopholes that pose a threat to public health.
GCE/RCE/TCE	Articulate the role of pharmacist in naloxone treatment.
	Discuss traditional and evidence-based alternatives to opioid therapy for chronic pain management.
	 Apply available screening tools to help identify and assess patients whose opioid use puts them at increased risk for harm.
	Highlight worsening epidemiological trends, despite the increasing awareness.
	 Detail the persistent threat of illicit fentanyl, fentanyl derivatives, ketamine and kratom use.
10:55-	Where are we With Marijuana and the Smoking Truth About Vaping?
11:45am	Presenters Track 1 – Lorenzo Porras, PharmD, PGY1 (SMB); Track 2 – Kathy Wong, PharmD, PGY1 (MVA)
	At the end of this session participants will be able to:
GCE/RCE/TCE	Examine the legal status and use of marijuana and its derivatives in the United States.
	 Describe e-cigarettes & compare/contrast vaping and juuling and FDA stand on these products.
	 Describe the impact that vaping and other pharmacological therapies for tobacco smoking cessation.
	 Examine the adverse effects of using recreational e-cigarettes, marijuana, vaping, and juuling.
	 Raise public awareness to prevent adolescents, teens, and adults from smoking e-cigarettes and tobacco products.
11:45pm-12:45	
12:45-1:35pm	Track 1 – ADHD Drugs and Stimulant Misuse in Adults. Kemel Zaldivar, Pharm.D., PGY1 (UMH)
12.43 1.33pm	Track 2 – Abuse and Misuse of Stimulants for ADHD. Rita Chamoun, PharmD, PGY1 (BHM)
GCE/RCE/TCE	At the end of this session participants will be able to:
	Compare and contrast the clinical manifestations and criteria for diagnosis of attention deficit hyperactivity disorder in adults and children.
	 Identify prevalence of misuse and comorbidity with adult ADHD and Review treatment options
	Demonstrate understanding of ADHD drugs and regulatory/legal requirements
	Summarize patient counseling points for vulnerable adult ADHD patients
1:35-2:25pm	Track 1 – PTSD Treatments in Light of Societal Issues for the Young and Old.
1.33-2.23pm	Claudia Nunez Chiang, PharmD, PGY1 (PGH). Track 2 – Management of PTSD: A Societal Burden Among the
GCE/RCE/TCE	
GCL/NCL/TCL	Elderly, the Young, and Veterans of this Country! Jarrett Johnson, PharmD, PGY2 Psychiatry (MVA)
	At the end of this session participants will be able to:
	Describe PTSB and Identify the physical, mental, and emotional symptoms that may occur. Describe PTSB and Identify the physical, mental, and emotional symptoms that may occur.
	Recognize the social, emotional, and economic burden of PTSD in young adults, elderly, and veteran populations. To a proper of the social property of the property o
2 2 2 2 2	Discuss current first line treatment options for PTSD.
	Break
2:35-3:25pm	Track 1 – Get Your Long-Acting Injectable (LAI) Antipsychotic Here! Andrew Karas, PharmD, PGY2 Psyc (NSU)
GCE/RCE/TCE	Track 2 – <u>Long-Acting Injectable Antipsychotics: The Pharmacist's Role.</u> Manuel Del Rio, PharmD, PGY2
	Administration (MVA). At the end of this session participants will be able to:
	Review and discuss currently available LAI antipsychotics and their place in therapy.
	Interpret current legislation(465.1893) regarding pharmacists' involvement in the administration of LAI antipsychotics.
	Evaluate and discuss the potential for pharmacists' involvement in LAI programs or clinics.

Discuss indications for oral and long acting injection antipsychotic medications and approaches to transitioning patients

between these agents.

GCE/RCE/TCE T T P P P P P P P P P P P P P P P P P	Track 1 – <u>Updates in the Treatment of Alzheimer's Disease, Nothing to Forget About.</u> Jessica Greenwood, PharmD, PGY1 (BHM) Track 2 – <u>Management of Dementia and Alzheimer's with a Focus on Updated Therapies.</u> Brittany Ball, PharmD, PGY1 (MVA). At the end of this session participants will be able to: • Define Alzheimer's and types of dementia and review their pathophysiology, diagnosis and therapeutic management	C N S
GCE/RCE/TCE T P	Track 2 – Management of Dementia and Alzheimer's with a Focus on Updated Therapies. Brittany Ball, PharmD, PGY1 (MVA). At the end of this session participants will be able to: • Define Alzheimer's and types of dementia and review their pathophysiology, diagnosis and therapeutic management	N
4:15-5:05pm T	PGY1 (MVA). At the end of this session participants will be able to: • Define Alzheimer's and types of dementia and review their pathophysiology, diagnosis and therapeutic management	
4:15-5:05pm T	• Define Alzheimer's and types of dementia and review their pathophysiology, diagnosis and therapeutic management	1.5
*		`
-	to all often a considerance and affect and all amounts of affect to a transfer out and the constant	Ι
*	including non-pharmacological and pharmacological treatment options.	U
*	 Review how to manage disease complications. Evaluate clinical impact of new drug therapies on disease progression in early/late phases of Alzheimer's disease. 	P
-	Track 1 – Complications and Treatment of Epilepsy. Gary Burdge, PharmD, PGY2 Psychiatry (NSU)	⊢ р
	Track 2 – <u>Update on Epilepsy - Newer Treatment Options</u> . Kamarena Sankar, PharmD, PGY2 Critical Care (BHM)	A
CCE/DCE/TCE	At the end of this session participants will be able to:	
	Review the clinical presentation, diagnosis and pathophysiology of epilepsy (acute v.s. maintenance).	Т
	 Examine the pharmacology, pharmacokinetics and clinical indications of currently available antiepileptic medication. 	E
	• Describe new treatment options for epilepsy.	S
	• Discuss the impact of legislation on patient access to these new therapies.	
	Sunday, January 27, 2019	
8:00-8:50am T	Treatment of Pulmonary Hypertension	4.
-	Presenters: Track 1 – Lissette Bauza, PharmD, PGY1 (SMB); Track 2 – Neisy Vazquez, PharmD, PGY1 (UMH)	HF
CCE/DCE/TCE	At the end of this session participants will be able to:	
	Distinguish the etiologies and pathophysiology associated with the different WHO classification groups of pulmonary	
	hypertension.	
	• Identify the pharmacological agents approved and under investigation for treatment of pulmonary arterial hypertension.	
	• Recognize the adverse drug reactions associated with the pharmacological agents used for treatment.	Ι.
	Explain treatment algorithms for pulmonary arterial hypertension.	↓ '
	Track 1 – <u>I Can't Breathe</u> . Mayret Gonzalez, PharmD, PGY1 (HH)	S
CCE/DCE/TCE	Track 2 – Pharmacological Management of Cystic Fibrosis- Exploring the Therapeutic Advancements in Cystic	E
· · · ·	Fibrosis. Jessica Justiz, PharmD, PGY1 (BHM)	Δ
Δ	At the end of this session participants will be able to:	
	Describe cystic fibrosis and its incidence in the population.	S
	Discuss updates in therapeutic management for patients with acute and chronic cystic fibrosis.	E
	Analyze different therapeutic options and cost saving alternatives. The same label and saving a linear size of the saving alternatives.	
0.40.0.50	Formulate appropriate counseling points for a cystic fibrosis patient. reak	⊣ T
	·····	R
	Update on Multiple Sclerosis and ALS Therapies Presenters: Track 1 – Brenda Mendez Guzman, PharmD, PGY2 Admin (MVA); Track 2 - Ikponmwosa Urhoghide,	E
CCE/DCE/TCE	PharmD, PGY1 (PGH)	
•	At the end of this session participants will be able to:	A
*	Recognize differences between multiple sclerosis and amyotrophic lateral sclerosis.	T
	 Discuss drug treatment for both disease states including disease Modifying Therapies (DMT) used in the management of MS. 	N
	 Recognize current therapies available for ALS management. 	E
	Identify common adverse reactions and monitoring parameters for drug treatment.	
10:40- C	Oral Anticoagulants and Their Reversals: An Update.	- N
	Presenters: Track 1 – Elaina Rosario, PharmD, PGY2 Ambulatory (NSU); Track 2 - Carolyn Ruiz, PharmD, PGY1	T
((BHM). At the end of this session participants will be able to:	
GCE/RCE/TCE	Describe the place in therapy as well as the differentiating characteristics of the oral anticoagulants, including indications	U
	and dosing requirements.	P
	• Explain the risk factors for bleeding complications from the use of oral anticoagulants and strategies for minimizing the risk.	
	• Review current and emerging approaches to reversing the effects of oral anticoagulants in patients with major or life-	
	threatening bleeding.	A
	 Define the pharmacist's role in the selection/monitoring of anticoagulation and reversal agents. 	_ T
	Nutraceuticals and Their Role in Health	E
	Presenters: Track 1 – Diana Cifuentes, PharmD, PGY1 (MVA); Track 2 – Heba Younes, PharmD, PGY1 (LH)	S
CCE/DCE/TCE A	At the end of this session participants will be able to:]
GCE/RCE/TCE	Identify different types of nutraceuticals.	
	• Explain the role of nutraceuticals in current health care practice.	
	Identify opportunities for pharmacist involvement in educating patients about nutraceutical use and their impact in patient	
12:20= 1:20	care.	\vdash
12:20pm-1:20pm	Lunch	4

1:20-2:10pm	Track 1 – The Evolution of Telehealth. Nichelle Logan, PharmD, PGY2 Ambulatory (NSU)		
Track 2 – <u>Telepharmacy: The Future of Pharmacy Services</u> . Monica Tadros, PharmD, PGY1 (BHM)			
GCE/RCE/TCE	ble to:		
	Compare and contrast telehealth, telemedicine, a		
	Explain the pros and cons of the use of telehealth		
	Compare models and Identify settings and popular		
	Describe the applications of telepharmacy in curr	·	
	Evaluate the impact of telemedicine and telepha		
2:10-3:00pm	Computer Alert! - QT Prolongation – Flag Fatigu		
CCE/DCE/TCE	Presenters: Track 1 – Rucha Acharya, PharmD, PGY1 Community (NSU); Track 2 – Julia Gonzalez, PharmD, PGY1 Community (NSU); Track 2 – Julia Gon		
GCE/RCE/TCE	(MHW). At the end of this session participants	will be able to:	
	 Describe the relationship between prolonged QT 	·	
	 Identify risk factors for QTc prolongation and tors 	sade de pointes.	
	 Review drugs that cause QT prolongation, focusir 		
	 Discuss appropriate monitoring during therapy w 		
	 Discuss notification fatigue, and its role the safe of 	dispensing of medication.	
3:00-3:10pm	Break		
3:10-4:00pm	Track 1 – Beyond the Hospital Doors – The Futu	re of Transitions of Care. Lorena Berrios Caldero, PharmD, PGY1	
	(WKBH); Track 2 – Transitions of Care: Where D	Oo We Go From Here? Heidi Feliciano, PharmD, PGY1 (MH)	
GCE/RCE/TCE At the end of this session participants will be able to:			
	Define transitions of care (TOC) and the pharmac	ist's role during this process.	
	Describe strategies for the optimization of transit		
	Identify common barriers and challenges present	in the process of transitioning patients from secondary to primary care.	
	Analyze current transitions of care models and de-	escribe the impact of a successful program on patient outcomes.	
4:00-4:50pm	USP 797 and 800: Updates Are ComingIs Your		
	-	PGY1 (MVA), Track 2 – Alyssa Donadio, PharmD, PGY2 Oncology	
GCE/RCE/TCE	(BHM). At the end of this session participants v	· · · · · · · · · · · · · · · · · · ·	
		SP 800 and identify key differences between the two chapters.	
		97 and USP 800 as well as timelines for implementation.	
		y encounter in implementing new standards of USP chapters 797 and 800.	
		,	
Tue Day Educa	tion Designation (46 total and 4 house) belong but	Daily Education Basistantian (Obs Catuaday on Obs Conday)	
	ation Registration (16 total credit hours). Includes hot on Saturday & Sunday with 2hr Medication Error	Daily Education Registration (8hr Saturday or 8hr Sunday)	
DIEGNIASI & IUIICII	Before 1/19/19 After 1/19/19	Select the day you will attend:	
□ DCPA Membe		□ Saturday including meals OR □ Sunday including meals	
□ Non Member	· · · · · · · · · · · · · · · · · · ·	□ Vegetarian Meal Request (pre-registration only) Before 1/19/19 After 1/19/19	
	nbers who have not renewed for 2019)	□ DCPA Member RPh & Tech \$175 \$215	
□ Non Member	·	□ Non Member RPh inc. dues \$255 \$305	
	Ψ250 Ψ010	□ Non Member Tech inc. dues \$215 \$265	
□ Vegetarian M	leal Request (pre-registration only)	ψ203 ψ213 ψ203	
= rogotanan m	our request (pro region unon emy)	Only interested in the Saturday 2hr Medication Error	
2019 calendar v	ear dues are \$80 pharmacists; \$40 technicians and	Before 1/19/19 After 1/19/19	
	L subscription to CE Broker. Checks must be	□ Pharmacist & Tech \$50 \$70	
	1/14/2019 to receive pre-registration rate.	No meals are included in this program registration.	
		The Program "Handouts" will be posted on our web site	
Unline regi	istration is available with credit card		
	at www.dcpa.us/CE.html	www.dcpa.us/CE.html for free download and/or printing to	
	OR	bring to the meeting. (Note: Free WiFi is only available in the	
PI FASE MAI	IL YOUR COMPLETED REGISTRATION FORM	Lobby of the Hotel for downloading).	
I LEAGE WA	WITH PAYMENT TO:	,	
DCDA 40		WE WILL NOT BE PROVIDING PRINTED HANDOUTS	
	271 NE 97th Street, Miami Shores, FL 33138	WE WILL NOT BE PROVIDING PRINTED HANDOUTS.	
REGISTRATIO	ON FORM	Pre-registration Deadline: Saturday, January 19, 2019	
Name .			
Name:			
۸ ما ماسم ·			
Address:			
City State 7im			
City, State, Zip:			
Email:			
Florida Licen	nse: Pharmacist: PS#: Consul	tant: PU# Registered Technician: RPT#	